The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen

Psychopharmacology (Berl). 2010 Apr;209(2):163-74. doi: 10.1007/s00213-010-1784-0. Epub 2010 Feb 19.

Abstract

Rationale: Hallucinogenic serotonin 2A (5-HT(2A)) receptor partial agonists, such as (+ or -)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane hydrochloride (DOI), induce a frontal cortex-dependent head-twitch response (HTR) in rodents, a behavioral proxy of a hallucinogenic response that is blocked by 5-HT(2A) receptor antagonists. In addition to 5-HT(2A) receptors, DOI and most other serotonin-like hallucinogens have high affinity and potency as partial agonists at 5-HT(2C) receptors.

Objectives: We tested for involvement of 5-HT(2C) receptors in the HTR induced by DOI.

Results: Comparison of 5-HT(2C) receptor knockout and wild-type littermates revealed an approximately 50% reduction in DOI-induced HTR in knockout mice. Also, pretreatment with either the 5-HT(2C) receptor antagonist SB206553 or SB242084 eradicated a twofold difference in DOI-induced HTR between the standard inbred mouse strains C57BL/6J and DBA/2J, and decreased the DOI-induced HTR by at least 50% in both strains. None of several measures of 5-HT(2A) receptors in frontal cortex explained the strain difference, including 5-HT(2A) receptor density, Galpha(q) or Galpha(i/o) protein levels, phospholipase C activity, or DOI-induced expression of Egr1 and Egr2. 5-HT(2C) receptor density in the brains of C57BL/6J and DBA/2J was also equivalent, suggesting that 5-HT(2C) receptor-mediated intracellular signaling or other physiological modulators of the HTR may explain the strain difference in response to DOI.

Conclusions: We conclude that the HTR to DOI in mice is strongly modulated by 5-HT(2C) receptor activity. This novel finding invites reassessment of hallucinogenic mechanisms involving 5-HT(2) receptors.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Aminopyridines / pharmacology
  • Amphetamines / pharmacology*
  • Animals
  • Autoradiography
  • Behavior, Animal*
  • Binding Sites
  • Blotting, Western
  • Brain / drug effects*
  • Brain / metabolism
  • Dose-Response Relationship, Drug
  • Drug Partial Agonism
  • Early Growth Response Protein 1 / genetics
  • Early Growth Response Protein 2 / genetics
  • GTP-Binding Protein alpha Subunits, Gi-Go / metabolism
  • GTP-Binding Protein alpha Subunits, Gq-G11 / metabolism
  • Hallucinogens / pharmacology*
  • Head Movements / drug effects*
  • Indoles / pharmacology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Inbred DBA
  • Mice, Knockout
  • Pyridines / pharmacology
  • RNA, Messenger / metabolism
  • Receptor, Serotonin, 5-HT2C / deficiency
  • Receptor, Serotonin, 5-HT2C / drug effects*
  • Receptor, Serotonin, 5-HT2C / genetics
  • Serotonin Antagonists / pharmacology
  • Serotonin Receptor Agonists / pharmacology*
  • Species Specificity
  • Type C Phospholipases / metabolism

Substances

  • 6-chloro-5-methyl-1-((2-(2-methylpyrid-3-yloxy)pyrid-5-yl)carbamoyl)indoline
  • Aminopyridines
  • Amphetamines
  • Early Growth Response Protein 1
  • Early Growth Response Protein 2
  • Egr1 protein, rat
  • Egr2 protein, rat
  • Hallucinogens
  • Indoles
  • Pyridines
  • RNA, Messenger
  • Receptor, Serotonin, 5-HT2C
  • Serotonin Antagonists
  • Serotonin Receptor Agonists
  • SB 206553
  • Type C Phospholipases
  • GTP-Binding Protein alpha Subunits, Gi-Go
  • GTP-Binding Protein alpha Subunits, Gq-G11
  • 4-iodo-2,5-dimethoxyphenylisopropylamine